Kopran Limited (KOPRAN) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Kopran Limited ₹89.41, price ₹254, upside -64.8%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹92.90 – ₹338.12 · fair‑value band ₹69.88 – ₹116.23 · the ₹254.30 price screens above the ₹89.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Kopran in your weekly email
Every Wednesday you see whether Kopran is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally.
Show more
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
Stock analysis
Kopran Limited (KOPRAN) currently trades at ₹254.30, while our model-based Fair Value estimate is ₹89.41, 64.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹117.14 per share, and 0 of the 14 models we run sit above the ₹254.30 price.
Bear case: the Earnings-Based group reads lowest at ₹47.49, and 14 of the 14 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹69.88 (bear) to ₹116.23 (bull), the price of ₹254.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kopran Limited reported revenue of ₹6.8B in FY2026 versus ₹4.7B in FY2022, a compound +9.5%/yr. Reported net income was ₹257M in FY2026, compounding −19.4%/yr from FY2022.
Key figures
Market cap ₹13.7B (≈ $141M) · P/E ratio 48.4 · P/S ratio 1.83 · EPS (TTM) ₹5.25 · Dividend yield 1.1% · Net margin 3.8% · Return on equity 4.9% · Return on assets (EBIT) 10.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 13% below its 52-week high and 139% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −65%, KOPRAN screens richer than that median.
Fair Value models
Bear ₹69.88Fair Value ₹89.41Bull ₹116.23
Price ₹254.30 · Upside -64.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹2.76 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income₹75.29₹72.72₹74.2676
EPV₹75.18₹84.36₹91.8274
ROIC Compounder₹75.18₹84.36₹91.8272
All 14 models by family
Earnings-Based
Graham-Dodd₹36.21₹137.13₹185.6264
Lynch FV₹33.25₹47.49₹61.7461
PEG = 1.0₹33.25₹47.49₹61.7457
EPV₹75.18₹84.36₹91.8274
Multiples
P/E Multiple₹87.85₹117.14₹146.4263
P/S Multiple₹67.89₹90.52₹113.1558
P/B Multiple₹67.89₹90.52₹113.1555
EV/EBIT₹158.04₹211.18₹264.3266
EV/EBITDA₹167.87₹224.28₹280.7067
EV/Revenue₹112.40₹161.16₹209.9353
Asset-Based
NCAV (Graham)₹54.86₹73.52₹109.7354
Economic Profit
Residual Income₹75.29₹72.72₹74.2676
ROIC Compounder₹75.18₹84.36₹91.8272
Growth Earnings
Growth-Adj P/E₹62.59₹89.41₹116.2367
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Start year 2021 (pandemic). Over 10 years: +8.7% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−14.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.9%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−15.9% vs 4.2%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 9%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−64.8% · Bottom 25%
Profitability
Return on equity (TTM)4.9% · Below median
Return on assets4.3% · Below median
Net margin (TTM)3.6% · Below median
Operating margin (TTM)6.5% · Below median
Growth and dividend
Revenue growth13.9% · Above median
Dividend yield (TTM)1.1% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (TTM)48.4× · Priciest 25%
P/B2.58× · Pricier than median
P/S (TTM)1.95× · Cheaper than median
EV/EBITDA17.8× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)70· sector 33
PAST (return on equity)20· sector 40
HEALTH (low debt)99· sector 92
DIVIDEND (yield)21· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Kopran Limited Fair Value". https://www.fairvalue-calculator.com/stock/KOPRAN
Frequently asked questions
Is Kopran Limited (KOPRAN) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹89.41 versus a price of ₹254.30, about −65% upside (overvalued).
What is the fair value of KOPRAN?
Our model-based fair value for Kopran Limited is ₹89.41 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹254.30.
What is the quality score of KOPRAN?
Kopran Limited has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kopran Limited (KOPRAN)?
Our model-based price target is the fair value of ₹89.41 (as of Oct 3, 2026) from 14 valuation models. Cautious scenario ₹69.88, optimistic scenario ₹116.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Kopran Limited stock forecast for 2026?
Our models put fair value at ₹89.41, about −65% upside versus a price of ₹254.30 (overvalued). Cautious scenario ₹69.88, optimistic scenario ₹116.23. The calculation is refreshed regularly with new filings.
What is the revenue of Kopran Limited (KOPRAN)?
Kopran Limited reported trailing-twelve-month revenue of about ₹7.0B (latest available figure, as of Oct 3, 2026).
Does Kopran Limited pay a dividend?
Kopran Limited currently shows a dividend yield of about 1.06% relative to its recent price (as of Oct 3, 2026).
What is the intrinsic value of Kopran Limited (KOPRAN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kopran Limited it is ₹89.41 per share (as of Oct 3, 2026), against a price of ₹254.30. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Kopran Limited stock overvalued or undervalued in 2026?
As of Oct 3, 2026, KOPRAN trades above its calculated fair value: price ₹254.30, fair value ₹89.41, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KOPRAN?
No. The price is what the market pays today (₹254.30); the fair value is what the company's own numbers justify (₹89.41). For Kopran Limited the two are ₹164.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kopran Limited worth?
The market values Kopran Limited at about ₹13.7B (market capitalisation, as of Oct 3, 2026). Per share that is ₹254.30; our models calculate a fair value of ₹89.41 per share.
What do the bullish and bearish scenarios say about KOPRAN?
Our models span a range for Kopran Limited: cautious scenario ₹69.88, base ₹89.41, optimistic ₹116.23 per share (as of Oct 3, 2026, price ₹254.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KOPRAN?
Kopran Limited trades at a price-to-earnings ratio of 48.4 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹89.41 is built from several models across several years. Other multiples: P/B 2.6, P/S 2.0, EV/EBITDA 17.8.
How solid is the balance sheet of Kopran Limited (KOPRAN)?
Balance-sheet figures for Kopran Limited (as of Oct 3, 2026): return on equity 4.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is KOPRAN from its 52-week high?
Kopran Limited trades at ₹254.30, about 13% below its 52-week high of ₹290.90 and 139% above the low of ₹106.22 (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of ₹89.41 is for.
Which stocks are comparable to Kopran Limited?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kopran Limited stock attractive at the current price?
The data as of Oct 3, 2026: price ₹254.30, calculated fair value ₹89.41 (−65%), Quality Score 49/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KOPRAN calculated?
We run Kopran Limited through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹89.41, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Kopran Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kopran Limited (KOPRAN)?
The closing price on Oct 8, 2026 was ₹254.30. Our model-based fair value is ₹89.41, about −65% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kopran Limited right now?
The price sits above even our optimistic bull case (₹116.23). The favourable scenario is already priced in. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Kopran Limited (KOPRAN) come from?
Earnings per share at Kopran Limited grew +10.0 % a year from 2016 to 2026. Broken into its drivers: revenue per share +7.8 %, EBIT margin +11.7 %, tax rate −3.3 %, residual (interest, one-offs) −5.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Kopran Limited
How large is the market capitalisation of Kopran Limited (KOPRAN)?
The market capitalisation of Kopran Limited is ₹13.7B (≈ $141M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kopran Limited (KOPRAN)?
The price-to-sales ratio of Kopran Limited is 1.83 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kopran Limited (KOPRAN)?
Earnings per share at Kopran Limited are ₹5.25 (price ÷ EPS = P/E 48.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kopran Limited (KOPRAN)?
The dividend yield of Kopran Limited is 1.1% (payout 51.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kopran Limited (KOPRAN)?
The net margin of Kopran Limited is 3.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kopran Limited (KOPRAN)?
The return on equity (ROE) of Kopran Limited is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kopran Limited (KOPRAN)?
On an EBIT basis the return on assets of Kopran Limited is 10.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kopran Limited (KOPRAN)?
The operating margin of Kopran Limited is 6.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kopran Limited (KOPRAN)?
Revenue at Kopran Limited is growing +13.9% versus a year earlier (3y avg +7.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kopran Limited (KOPRAN)?
Earnings per share at Kopran Limited are growing −9.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kopran Limited (KOPRAN) generate?
The free cash flow of Kopran Limited is −₹105M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kopran Limited (KOPRAN) carry?
The net debt of Kopran Limited is ₹1.5B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kopran Limited in the live analysis
One click puts Kopran Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
